Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ: JAZZ )

137.96 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 25
Open 137.96
Bid (Size) 125.00 (1)
Ask (Size) 145.46 (2)
Prev. Close 137.96
Today's Range 137.96 - 137.96
52wk Range 99.06 - 148.06
Shares Outstanding 62,311,104
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals.
JAZZ PHARMACEUTICALS PLC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:JAZZ showcases decent financial health and profitability, coupled with an attractive price. 
Via Chartmill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
From Brodsky & Smith LLC
Via GlobeNewswire

Performance

YTD
+11.47%
+11.47%
1 Month
+2.99%
+2.99%
3 Month
+10.19%
+10.19%
6 Month
+25.91%
+25.91%
1 Year
+11.79%
+11.79%

More News

Read More
DraftKings To Rally Over 29%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
A Glimpse Into The Expert Outlook On Jazz Pharmaceuticals Through 12 Analysts
Via Benzinga
Earnings Scheduled For February 25, 2025
Via Benzinga
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
Via Benzinga
Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251
Via Benzinga
Topics Earnings
Exposures Financial
3 Highly Ranked Medical Stocks To Buy Amid Recent Market Volatility: JAZZ, OPCH, PCRX
Via Talk Markets
Topics Stocks / Equities
Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline
Via Benzinga
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
From Chimerix, Inc.; Jazz Pharmaceuticals plc
Via GlobeNewswire
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
Via Investor's Business Daily
3 Small-Cap Stocks Skating on Thin Ice
Via StockStory
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Via StockStory
Viatris Earnings: What To Look For From VTRS
Via StockStory
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Via StockStory
NASDAQ:JAZZ is probably undervalued for the fundamentals it is displaying.
Via Chartmill
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga
Investors should take notice of NASDAQ:JAZZ—it offers a great deal for the fundamentals it presents.
Via Chartmill
NASDAQ:JAZZ, an undervalued stock with good fundamentals.
Via Chartmill
NASDAQ:JAZZ is an undervalued gem with solid fundamentals.
Via Chartmill
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements
Via Benzinga
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says
Via Benzinga
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
Via Chartmill
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.